Renée Maas

331 Modeling and Rescue of PLN-R14del Cardiomyopathy Phenotype in Human iPSC-Derived Cardiac Spheroids 12 51. Olofsson, S. O. et al. Triglyceride containing lipid droplets and lipid droplet-associated proteins. Curr. Opin. Lipidol. 19, (2008). 52. Volmer, R., van der Ploeg, K. & Ron, D. Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. Proc. Natl. Acad. Sci. U. S. A. 110, 4628– 4633 (2013). 53. Jao, T.-M. et al. ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis. Kidney Int. 95, 577–589 (2019). 54. Zoncu, R. et al. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 334, 678–683 (2011). 55. Theis, J. L. et al. TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy. Hum. Mol. Genet. 23, 5793–5804 (2014). 56. Lennermann, D., Backs, J. & van den Hoogenhof, M. M. G. New Insights in RBM20 Cardiomyopathy. Curr. Heart Fail. Rep. 17, 234–246 (2020). 57. Aye, T.-T. et al. Reorganized PKA-AKAP associations in the failing human heart. J. Mol. Cell. Cardiol. 52, 511–518 (2012). 58. Figtree, G. A., Bubb, K. J., Tang, O., Kizana, E. & Gentile, C. Vascularized Cardiac Spheroids as Novel 3D in vitro Models to Study Cardiac Fibrosis. Cells Tissues Organs 204, 191–198 (2017). 59. Li, B. et al. Knockdown of eIF3a ameliorates cardiac fibrosis by inhibiting the TGF-β1/Smad3 signaling pathway. Cell. Mol. Biol. 62, 97–101 (2016). 60. Sarrazy, V. et al. Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction. Cardiovasc. Res. 102, 407–417 (2014). 61. Hinz, B., Dugina, V., Ballestrem, C., Wehrle-Haller, B. & Chaponnier, C. Alpha-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts. Mol. Biol. Cell 14, 2508–2519 (2003). 62. Hall, C. et al. Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype. Sci. Rep. 13, 12137 (2023). 63. Eijgenraam, T. R. et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci. Rep. 10, (2020). 64. Te Rijdt, W. P. et al. Distinct molecular signature of phospholamban p.Arg14del arrhythmogenic cardiomyopathy. Cardiovasc. Pathol. 40, (2019). 65. Schmitt, J. P. et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, (2003). 66. Medeiros, A. et al. Mutations in the human phospholamban gene in patients with heart failure. Am. Heart J. 162, (2011). 67. Landstrom, A. P., Adekola, B. A., Bos, J. M., Ommen, S. R. & Ackerman, M. J. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing. Am. Heart J. 161, (2011). 68. Pellman, J., Zhang, J. & Sheikh, F. Myocyte-fibroblast communication in cardiac fibrosis and arrhythmias: Mechanisms and model systems. J. Mol. Cell. Cardiol. 94, 22–31 (2016). 69. Burke, M. A. et al. Molecular profiling of dilated cardiomyopathy that progresses to heart failure. JCI insight 1, (2016). 70. Hall, C., Gehmlich, K., Denning, C. & Pavlovic, D. Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease. J. Am. Heart Assoc. 10, (2021). 71. Nattel, S. & Harada, M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J. Am. Coll. Cardiol. 63, (2014). 72. MacLean, J. & Pasumarthi, K. B. Signaling mechanisms regulating fibroblast activation, phenoconversion and fibrosis in the heart. Indian J. Biochem. Biophys. 51, (2014). 73. Tissue expression of NTN1 - Summary - The Human Protein Atlas. https://www.proteinatlas.org/ ENSG00000065320-NTN1/tissue. 74. Wu, G. et al. Suppression of Netrin-1 attenuates angiotension II-induced cardiac remodeling through the PKC/ MAPK signaling pathway. Biomed. Pharmacother. 130, 110495 (2020).

RkJQdWJsaXNoZXIy MTk4NDMw